Thyroid cancers express CD-40 and CD-40 ligand: Cancers that express CD-40 ligand may have a greater risk of recurrence in young patients

Thyroid

Volumn 15, Issue 2, 2005, Pages 105-113

  Costello, Amy ^a   Rey Hipolito, Christine ^b   Patel, Aneeta ^b   Oakley, Kevin ^b   Vasco, Vasyl ^b   Calabria, Chris ^b   Tuttle, R Michael ^c   Francis, Gary L ^b  

^a Wright Patterson Medical Center   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND;

ADOLESCENT; ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MALE; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; WESTERN BLOTTING;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIGENS, CD40; CARCINOMA, PAPILLARY; CD40 LIGAND; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM RECURRENCE, LOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 14844297005     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2005.15.105     Document Type: Article

References (23)

1. National Cancer Institute, SEER Program. NIH 1999 Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD.
2. Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63:908-911.
3. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 49:619-628.
4. McClellan DR, Francis GL 1996 Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 25:27-48.
5. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424.
6. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R, Francis GL 2001 Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab 86:1346-1354.
7. Modi J, Patel A, Terrell R, Gupta S, Fenton C, Tuttle R, Francis G 2003 Papillary thyroid carcinoma from children and adolescents contain a mixture of lymphocytes. J Clin Endocrinol Metab 88:4418-4425.
8. alpha promoter. Thyroid 8:361-369.
9. Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Nakamura H, Kimura H, Ishikawa N, Ito K, Nagataki S 1996 Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. J Clin Endocrinol Metab 81:4137-4143.
10. Shah R, Banks K, Patel A, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis GL 2002 Intense expression of the b7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents. J Clin Endocrinol Metab 87:4391-4397.
11. Kornbluth RS 2002 An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 11:787-801.
12. van Kooten C, Banchereau J 2000 CD40-CD40 ligand. J Leukoc Biol 67:2-17.
13. Tong AW, Stone MJ 2003 Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10:1-13.
14. Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR 2002 CD40 activation as potential tool in malignant neoplasms. Tumori 88:361-366.
15. Kuwashima N, Kageyama S, Eto Y, Urashima M 2001 CD40 ligand immunotherapy in cancer: an efficient approach. Leuk Lymphoma 42:1367-1377.
16. Yamada, Sayegh MH 2002 The CD154-CD40 costimulatory pathway in transplantation. Transplantation 73:S36-S39.
17. Kie JH, Cho MS, Yang WI 2001 Expression of CD40 and apoptosis related molecules in autoimmune thyroid diseases. Yonsei Med J 42:488-496.
18. Smith TJ, Sciaky D, Phipps RP, Jennings TA 1999 CD40 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid 9:749-755.
19. Fujieda S, Sugimoto C, Seki M, Sunaga H, Saito H 1998 CD40 stimulation inhibits cell growth and Fas-mediated apoptosis in a thyroid cancer cell line. Oncol Res 10:433-439.
20. Metcalfe RA, McIntosh RS, Marelli-Berg F, Lombardi G, Lechler R, Weetman AP 1998 Detection of CD40 on human thyroid follicular cells: analysis of expression and function. J Clin Endocrinol Metab 83:1268-1274.
21. Resetkova E, Kawai K, Enomoto T, Arreaza G, Togun R, Foy TM, Noelle RJ, Volpe R 1996 Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. Thyroid 6:267-273.
22. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058.
23. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498.